EFTUD2 and mandibulofacial dysostosis-microcephaly syndrome: [7, 8] While 70% of MFDM cases result from de novo EFTUD2 mutations,[9] the molecular mechanisms linking these genetic alterations to phenotypic manifestations remain poorly understood, impeding the development of targeted therapies.